Rituximab treatment in myasthenia gravis
Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%–30% of patients are refractory to conventional treatments. For these patients, rituximab has been used off-label in the recent decades. Rituximab is a...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2023-10-01
|
| Serie: | Frontiers in Neurology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1275533/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|